Piperacillin, Tazobactam Drug Combination

ApprovedSmall molecule

AAzienda Sanitaria Universitaria Friuli Centrale

Piperacillin, Tazobactam Drug Combination is one of 32 small molecule programs targeting Appendicitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AppendicitisActive, not recruiting

AppendicitisApproved

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Appendicitis

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

2 2

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 3

Naropin

FFresenius Kabi Oncology Ltd.

Approved

1 4

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

—5

Decadron

AAspen Global Incorporated

Monurol

Levaquin

Marcaine

Merrem

BB. Braun Medical Inc.

Approved

—10

Ketalar

AAultman Health Foundation

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Intravenous

NCT07481539

Clinical

Trials by Indication[1]

Intravenous1 trial

Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment

Recruiting·AAzienda Sanitaria Universitaria Friuli Centrale·Phase 2·NCT07481539·240 enrolled

Appendicitis1 trial

Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

Completed·PPhoenix Children's Hospital·Phase 4·NCT03289351·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Piperacillin, Tazobactam Drug Combination. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Piperacillin, Tazobactam Drug Combination compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Piperacillin, Tazobactam Drug Combination. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Sanitaria Universitaria Friuli Centrale company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAzienda Sanitaria Universitaria Friuli Centrale

Piperacillin, Tazobactam Drug Combination

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Intravenous1 trial

Appendicitis1 trial

References

Drug Info

Quick Facts

Related News